Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Microfluidic Chip Can Diagnose Latent Tuberculosis

By LabMedica International staff writers
Posted on 06 Jun 2012
A microfluidic chip has been developed that can test for latent tuberculosis infection (LTBI) and maybe faster and more reliable than current testing for the disease.

Current tests for LTB are based on detecting the release of interferon-gamma (IFN-γ), a disease-fighting chemical made by cells of the immune system, which commercially available tests require sending samples to a laboratory, and can be used just once.

Biomedical engineers at University of California, Davis (UCD; CA, USA) developed a novel approach for the assay. More...
They coated a gold wafer with short pieces of a single-stranded DNA segment known to stick specifically to IFN-γ. They then mounted the wafer in a chip that has tiny channels for blood samples. If IFN-γ is present in a blood sample, it sticks to the DNA, triggering an electrical signal that can be read by a clinician.

The scientists plan to refine the system so that the microfluidic sensor and electronic readout are integrated on a single chip. An electrochemical biosensor for simple and sensitive detection of IFN-γ will have future applications in immunology, cancer research, and infectious disease monitoring. The team has already conducted testing of blood samples from patients in China and the USA. About one-third of the world's population is infected with the bacteria that cause tuberculosis, a disease that kills an estimated 1.5 million people worldwide every year, according to the US Centers for Disease Control and Prevention (CDC; Atlanta GA, USA).

Most infected people have latent TB, in which the bacteria are kept in check by the immune system. Patients become sick only when the immune system is compromised, enabling the bacteria to become active. People infected with the human immunodeficiency virus (HIV) are at especially high risk. Alexander Revzin, PhD, a professor in the UC Davis Department of Biomedical Engineering and his specialist Ying Liu, PhD, added, "Our assay is cheaper than other interferon-gamma release assays, is reusable, and gives results in real time. If you see that the IFN-γ level is high, you can diagnose latent TB."

Related Links:

University of California at Davis
US Centers for Disease Control and Prevention



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.